Clinical trials: Second-Line
Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Safety and efficacy of Cardonilmab as a second-line or above treatment in patients with advanced malignant melanoma and renal cell carcinoma.
- Trial name
- NCT06670300
- Testing
- cardonilimab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- YongZhang